跳至主要内容
临床试验/NCT03158545
NCT03158545已完成不适用

Efficacy Evaluation of 26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Cerebral Blood Flow in Healthy Adults

Northumbria University2 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2016年10月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
78
试验地点
2
主要终点
Cerebral Blood Flow

研究概览

简要总结

The purpose of this study is to investigate the effects of EPA- and DHA-enriched omega-3 polyunsaturated fatty acid dietary supplements on cerebral blood flow during a series of cognitive, mathematical subtraction tasks and subjective ratings of task difficulty before and after 26 weeks of supplementation

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
25 Years 至 49 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 25 to 49 years inclusive
  • Males and females
  • Self-report of good health

排除标准

  • English is not first language (some of the cognitive tasks have only been validated in native English speakers)
  • Habitual consumption of oily fish exceeds one fish meal per week (see Appendix I)
  • Habitual consumption of omega-3 dietary supplements in the previous 6 months
  • Habitual use of dietary supplements within the last month (defined as more than 3 consecutive days or 4 days in total; some supplements that do not impact upon cognitive function e.g. garlic, protein, calcium are allowed. Please check with the research team if you are unsure)
  • Are a smoker or consume any nicotine replacement products (e.g. chewing gum, e-cigarettes)
  • Food allergies or sensitivities to any of the ingredients contained in the investigational product or any other foodstuff
  • Pregnant, trying to get pregnant or breast feeding
  • Body Mass Index outside of the range 18-35 kg/m2
  • High blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg)
  • Currently taking blood pressure medication
  • Currently taking blood thinning medication (e.g. aspirin, warfarin, heparin)
  • Have a respiratory disorder that requires regular medication (Note: participants with asthma who only take their medication occasionally/as required are eligible for this study)
  • Have frequent migraines that require medication (more than or equal to 1 per month)
  • History or current diagnosis of drug/alcohol abuse
  • History of kidney or liver disease, or other severe diseases of the gastrointestinal tract (e.g. iron accumulation, iron utilization disorders, hypercalcaemia, hypercalcaemia), that are likely to interfere with metabolism/absorption/secretion of the product under investigation
  • History of neurological or psychiatric illness (excluding depressive illness and anxiety)
  • History of head trauma
  • Sleep disturbances and/or are taking sleep aid medication
  • Blood disorders (e.g. anaemia, haemophilia, thrombocytosis)
  • Diagnosis of type I or type II diabetes
  • Heart disorder, or vascular illness
  • Current diagnosis of depression and/or anxiety
  • Over- or under-active thyroid
  • Chronic gastrointestinal problems (e.g. Inflammatory Bowel Disease, Irritable Bowel Syndrome, celiac disease)
  • Any known active infections
  • Diagnosed with syphilis, hepatitis, the Human T - lymphotropic virus or the Human Immunodeficiency Virus
  • Current or past breast cancer diagnosis and/or a mastectomy
  • Health condition that would prevent fulfilment of the study requirements
  • Currently participating in or in the past 4 weeks participated in other clinical or nutrition intervention studies

研究组 & 干预措施

Olive oil Placebo

Placebo Comparator

3 x 1 g capsules daily Placebo: olive oil

干预措施: Olive oil Placebo (Dietary Supplement)

EPA-rich

Active Comparator

3 x 1 g capsules daily containing EPA-enriched oil

干预措施: EPA-rich (Dietary Supplement)

DHA-rich

Active Comparator

3 x 1 g capsules daily containing DHA-enriched oil

干预措施: DHA-rich (Dietary Supplement)

结局指标

主要结局

Cerebral Blood Flow

时间窗: Participants are assessed pre and post 6 months of supplementation

Near Infrared Spectroscopy Outcomes for cerebral blood flow measurment

次要结局

  • Cognitive Performance(Participants are assessed pre and post 6 months of supplementation)
  • Subjective Task Difficulty(Participants are assessed pre and post 6 months of supplementation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Philippa Jackson

Dr.

Northumbria University

研究点 (2)

Loading locations...

相似试验